Author

Subha Saha

Institutions: Broad Institute, Harvard University, Massachusetts General Hospital, Massachusetts Institute of Technology

Observed institutions: Broad Institute, Harvard University, Massachusetts General Hospital, Regional Centre for Biotechnology, Institute of Life Sciences, Massachusetts Institute of Technology

ORCID: 0000-0002-1244-435X

Observed ORCID: 0000-0002-1244-435X

OpenAlex ID: A5065193370

PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy

2023 · Peter G. Miller, Adam S. Sperling, et al. · Blood · 54

Transcriptomic Analysis Identifies RNA Binding Proteins as Putative Regulators of Myelopoiesis and Leukemia

2019 · Subha Saha, Krushna Chandra Murmu, et al. · Frontiers in Oncology · 25

Differential colitis susceptibility of Th1- and Th2-biased mice: A multi-omics approach

2022 · Sohini Mukhopadhyay, Subha Saha, et al. · PLoS ONE · 18

MIF confers survival advantage to pancreatic CAFs by suppressing interferon pathway‐induced p53‐dependent apoptosis

2022 · Voddu Suresh, Pujarini Dash, et al. · The FASEB Journal · 17

Molecular and epigenetic alterations in normal and malignant myelopoiesis in human leukemia 60 (HL60) promyelocytic cell line model

2023 · Jhinuk Basu, Swati Madhulika, et al. · Frontiers in Cell and Developmental Biology · 12

SMARCD1 negatively regulates myeloid differentiation of leukemic cells via epigenetic mechanisms

2022 · Subha Saha, Priyanka Samal, et al. · Blood Advances · 10

Dysregulated HELLS expression alters cellular processes and serves as a potential prognostic marker in acute myeloid leukemia

2026 · Swati Madhulika, T Sayamsmruti Panda, et al. · Journal of Biological Chemistry

Works count: 7

Citation count: 136

H-index: 6

I10-index: 6